These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31298558)

  • 1. Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
    Sorrentino A; Steinhorn B; Troncone L; Saravi SSS; Badole S; Eroglu E; Kijewski MF; Divakaran S; Di Carli M; Michel T
    Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H617-H626. PubMed ID: 31298558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entresto protected the cardiomyocytes and preserved heart function in cardiorenal syndrome rat fed with high-protein diet through regulating the oxidative stress and Mfn2-mediated mitochondrial functional integrity.
    Yeh JN; Yue Y; Chu YC; Huang CR; Yang CC; Chiang JY; Yip HK; Guo J
    Biomed Pharmacother; 2021 Dec; 144():112244. PubMed ID: 34601193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
    Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
    J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
    Vaskova E; Ikeda G; Tada Y; Wahlquist C; Mercola M; Yang PC
    J Am Heart Assoc; 2020 Jul; 9(13):e015640. PubMed ID: 32538237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic and transcriptomic signatures of chemogenetic heart failure.
    Spyropoulos F; Sorrentino A; van der Reest J; Yang P; Waldeck-Weiermair M; Steinhorn B; Eroglu E; Saeedi Saravi SS; Yu P; Haigis M; Christou H; Michel T
    Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H451-H465. PubMed ID: 35089810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
    Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
    Li X; Braza J; Mende U; Choudhary G; Zhang P
    Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sacubitril-valsartan on aging-related cardiac dysfunction.
    Telesca M; De Angelis A; Donniacuo M; Bellocchio G; Riemma MA; Mele E; Canonico F; Cianflone E; Torella D; D'Amario D; Patti G; Liantonio A; Imbrici P; De Luca A; Castaldo G; Rossi F; Cappetta D; Urbanek K; Berrino L
    Eur J Pharmacol; 2024 Sep; 978():176794. PubMed ID: 38968980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
    Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LCZ696 (sacubitril/valsartan) protects against cyclophosphamide-induced testicular toxicity in rats: Role of neprilysin inhibition and lncRNA TUG1 in ameliorating apoptosis.
    Salama RM; Abd Elwahab AH; Abd-Elgalil MM; Elmongy NF; Schaalan MF
    Toxicology; 2020 May; 437():152439. PubMed ID: 32197949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
    Sun J; Xu W; Hua H; Xiao Y; Chen X; Gao Z; Li S; Jing X; Du F; Sun G
    Biomed Pharmacother; 2020 Sep; 129():110410. PubMed ID: 32570118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
    Januzzi JL; Camacho A; Piña IL; Rocha R; Williamson KM; Maisel AS; Felker GM; Prescott MF; Butler J; Solomon SD;
    Circ Heart Fail; 2020 Jun; 13(6):e006946. PubMed ID: 32482089
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction.
    Vergaro G; Del Franco A; Carecci A; Ferrari Chen YF; Aimo A; Forini F; Nicolini G; Kusmic C; Faita F; Castiglione V; De Tata V; Pucci A; Musetti V; Burchielli S; Passino C; Emdin M
    Int J Cardiol; 2024 Aug; 409():132203. PubMed ID: 38795973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
    J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
    Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.